Flinn IW, et al. - Researchers carried out this phase II trial to assess the efficacy of bendamustine, bortezomib and rituximab in patients with previously untreated low-grade lymphoma. In the current work, the treatment regimen was well tolerated and produced high response rates, justifying further study of this regimen in patients with previously untreated lymphoma.